Yusheng Han Acquires 104,650 Shares of Burning Rock Biotech (NASDAQ:BNR) Stock

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) Director Yusheng Han bought 104,650 shares of Burning Rock Biotech stock in a transaction on Monday, June 22nd. The shares were acquired at an average price of $7.45 per share, for a total transaction of $779,642.50. Following the completion of the acquisition, the director owned 18,123,196 shares of the company’s stock, valued at approximately $135,017,810.20. This represents a 0.58% increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.

Yusheng Han also recently made the following trade(s):

• On Friday, June 26th, Yusheng Han bought 24,900 shares of Burning Rock Biotech stock. The stock was acquired at an average cost of $8.00 per share, with a total value of $199,200.00.
• On Wednesday, June 24th, Yusheng Han purchased 250,000 shares of Burning Rock Biotech stock. The stock was acquired at an average price of $8.00 per share, with a total value of $2,000,000.00.
• On Tuesday, June 23rd, Yusheng Han purchased 5,990 shares of Burning Rock Biotech stock. The stock was acquired at an average price of $7.50 per share, with a total value of $44,925.00.
• On Tuesday, June 16th, Yusheng Han acquired 111,110 shares of Burning Rock Biotech stock. The shares were acquired at an average price of $9.00 per share, for a total transaction of $999,990.00.
• On Friday, June 12th, Yusheng Han acquired 210,000 shares of Burning Rock Biotech stock. The stock was acquired at an average price of $9.25 per share, with a total value of $1,942,500.00.
• On Thursday, June 11th, Yusheng Han bought 24,760 shares of Burning Rock Biotech stock. The shares were acquired at an average cost of $8.74 per share, with a total value of $216,402.40.

Burning Rock Biotech Price Performance

NASDAQ BNR opened at $9.82 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.81 and a current ratio of 3.05. The stock has a market cap of $103.31 million, a price-to-earnings ratio of -11.98 and a beta of 1.32. The business has a 50 day simple moving average of $12.35 and a 200 day simple moving average of $19.96. Burning Rock Biotech Limited Sponsored ADR has a 52-week low of $3.23 and a 52-week high of $41.72.

Burning Rock Biotech (NASDAQ:BNR) last announced its quarterly earnings results on Tuesday, June 9th. The company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.29) by $2.09. The firm had revenue of $15.66 million for the quarter, compared to analyst estimates of $19.21 million. Burning Rock Biotech had a negative net margin of 11.57% and a negative return on equity of 10.98%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on BNR shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Burning Rock Biotech in a research report on Monday, April 20th. Wall Street Zen cut Burning Rock Biotech from a “buy” rating to a “hold” rating in a report on Saturday, June 13th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of “Sell”.

Institutional Investors Weigh In On Burning Rock Biotech

Several institutional investors have recently bought and sold shares of the company. Marshall Wace LLP acquired a new position in Burning Rock Biotech during the 4th quarter worth approximately $220,000. Prospera Financial Services Inc raised its holdings in shares of Burning Rock Biotech by 26.0% in the fourth quarter. Prospera Financial Services Inc now owns 31,185 shares of the company’s stock valued at $628,000 after purchasing an additional 6,430 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Burning Rock Biotech by 13.8% in the first quarter. Renaissance Technologies LLC now owns 35,407 shares of the company’s stock valued at $571,000 after purchasing an additional 4,290 shares during the last quarter. Finally, Crcm LP lifted its position in shares of Burning Rock Biotech by 13.8% in the third quarter. Crcm LP now owns 221,575 shares of the company’s stock worth $1,917,000 after purchasing an additional 26,809 shares in the last quarter. Institutional investors own 30.03% of the company’s stock.

About Burning Rock Biotech

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.